UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 620, 2025

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37852		98-0505495
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

(510) 474-0170

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001		PTGX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

~~Item~~On 2June 20, 2025, Protagonist Therapeutics, Inc.02, a Delaware corporation (the “Company”), held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). ~~Results~~As of the close of ~~Operations~~business ~~and~~on ~~Financial~~April 23, ~~Condition~~2025, the record date for the Annual Meeting, there were 61,957,230 shares of common stock, par value $0.00001 per share (the “Common Stock”), entitled to vote at the meeting.

OnItem ~~May 6, 2025, Protagonist Therapeutics, Inc~~5. ~~reported its financial results for the first quarter ended March 31, 2025~~07. ASubmission ~~copy~~ of ~~the~~Matters ~~press release titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update” is furnished pursuant~~ to ~~Item~~a ~~2.02~~Vote asof ~~Exhibit 99.1 hereto~~Security ~~and is incorporated herein by reference~~Holders.

~~Item~~At the Annual Meeting, the stockholders voted on 9the three proposals listed below.~~01 Financial~~ ~~Statements~~The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the Securities and ~~Exhibits~~Exchange Commission on April 29, 2025. The results of the proposals voted upon at the Annual Meeting were:

~~(d)~~Proposal 1 — To elect the two Class ~~Exhibits~~III director nominees to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Each of the two nominees was so elected, with the votes thereon as follows:

Exhibit No.	Description
		Final Voting Results
99.1	Press release, dated May 6, 2025, titled “Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update.”
Nominee		For	Withheld	Broker Non-Votes
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
Harold E. Selick, Ph.D.		44,822,907	9,210,036	1,918,517
Bryan Giraudo		42,499,790	11,533,153	1,918,517

~~The~~Proposal ~~information~~2 in— ~~this~~To ~~report~~approve, ~~including~~on ~~the~~a ~~exhibit hereto~~non-binding, ~~shall~~ ~~not~~advisory ~~be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934~~basis, ~~as amended, or otherwise subject to~~ the ~~liabilities~~compensation of ~~Section 11 and 12(a)(2) of~~ the ~~Securities~~Company’s ~~Act~~named ofexecutive ~~1933, as amended~~officers. ~~The~~This ~~information~~proposal ~~contained~~was ~~herein and~~approved ~~in the accompanying exhibit shall not be incorporated~~ by ~~reference into any filing with~~ the ~~U.S.~~requisite ~~Securities and Exchange Commission made by Protagonist Therapeutics~~vote, ~~Inc.,~~ ~~whether made before or after~~ with the ~~date~~votes ~~hereof,~~thereon ~~regardless~~as ~~of any general incorporation language in such filing.~~follows:

SIGNATURE

Final Voting Results
For	Against	Abstentions	Broker Non-Votes
50,844,517	2,850,473	337,953	1,918,517

~~Pursuant~~Proposal to3 ~~the~~— ~~requirements~~To ofratify the ~~Securities~~selection ~~Exchange~~of ~~Act~~Ernst & ofYoung ~~1934,~~LLP as the ~~Registrant~~Company’s ~~has~~independent ~~duly~~registered ~~caused~~public ~~this~~accounting ~~report~~firm tofor beits ~~signed~~fiscal onyear ~~its~~ending ~~behalf~~December 31, 2025. This proposal was approved by the ~~undersigned~~requisite ~~hereunto~~vote, ~~duly~~with ~~authorized.~~the votes thereon as follows:

Protagonist Therapeutics, Inc.

Final Voting Results

Dated: May 6, 2025

For

Against

Abstentions

Broker Non-Votes

By:

/s/ Asif Ali

55,480,739

74,233

396,488

Asif Ali

Chief Financial Officer

No other matters were submitted for stockholder action.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Protagonist Therapeutics, Inc.

Dated: June 26, 2025

	By:	/s/ Asif Ali
		Asif Ali
		Executive Vice President, Chief Financial Officer

Filing Compare · Protagonist Therapeutics, Inc